Leading national experts in the treatment of breast cancer point out that angiogenesis in the tumor microenvironment is the most essential factor in tumor growth and metastasis. When the volume of tumor does not exceed 2 cubic millimeters, the tumor has no independent blood supply and mainly relies on diffusion to obtain nutrition and is in resting stage. The VEGF family is the most intensively studied family of vascular factors, which is closely related to the growth, metastasis, pathological grading and prognosis of various tumors. For breast cancer, VEGF is expressed throughout its growth cycle, and the higher the level of VEGF, the worse the overall survival and recurrence-free survival of patients. Moreover, studies have shown that VEGF overexpression decreases the response of breast cancer patients to chemotherapy and endocrine therapy. The early effects of tumor vascularization against VEGF therapy include degradation of existing tumor microvasculature and normalization of surviving tumor vasculature, and the sustained effect is inhibition of new tumor vascularization. Intensive research on multiple pathways related to VEGF and VEGFR has facilitated the development of various mechanisms to target VEGF and VEGFR. Among them, bevacizumab, as the first recombinant, humanized, monoclonal anti-VEGF antibody, can inhibit angiogenesis and tumor growth by precisely inhibiting VEGF, exhibiting antitumor activity against breast cancer.